It’s the Idorsia team’s passion for science that will translate our objectives into value creation for all our stakeholders. We are doing more with less in a highly productive environment where people enjoy their work. Our Idorsia professionals show up with energy, intellect and creativity.
Professional background: Patty has demonstrated range of impact over a 20+ year career in the biotech and pharmaceutical industries. She brings broad and deep leadership experience, as well as industry-leading results, and a breadth of executive experience across therapeutic areas – from cardiovascular and metabolic to hematology, immunology, and respiratory, to neuroscience. Patty has deep relationships with customers from primary care to specialty and rare disease; as well as a track record of success at all stages of the product life cycle from preclinical to launch to patent expiration. Most recently she served as CSL Behring’s Vice President, Global Commercial Strategy for Thrombosis and Hemostasis; Shire Pharmaceuticals’ Executive Vice President Head of US Hematology; Johnson and Johnson’s Vice President US Sales and Marketing of the Cardiovascular and Institutional Business; GlaxoSmithKline’s Vice President of Global Commercial Strategy; and in several senior roles at AstraZeneca.
Education: Patty earned an MBA in Marketing from St. Joseph’s University and a B.S. in Public Health Education from East Carolina University.
Professional background: With over 35 years of pharma experience, Scotty was most recently Owner and President of Market Access GTN, LLC where he consulted with multiple BioPharma organizations on Market Access launch excellence. Prior to Market Access GTN, Scotty was SVP, US Market Access for Shire where he was responsible for the entire portfolio Market Access strategy, Specialty Distribution design and contracting, government price reporting, 3PL management, Government Affairs and Policy, strategic contracting with both public and private payers along with HUB service contracting and design. His therapeutic areas of focus include CNS, TNF Inhibitors, GI, Immunology, Hematology, Oncology, Renal, HIV, Endocrine, Ophthalmology, Pain, Cardiovascular, LSD, multiple rare and orphan drug categories.
Education: Scotty earned a Master Degree in Science and Jurisprudence from Seton Hall Law School and a BA in Biology at the College of Wooster.
Professional background: Bill has enjoyed a 30-year adventure in the pharma industry in both the generic and specialty brand arenas. He has designed, implemented and led a full range of corporate financial functions including strategic and operational planning in fast-paced, growth environments, including strategic planning, budgeting and forecasting, operations analysis, pipeline selection and valuation, M&A valuation, accounting operations, performance tracking and reporting, corporate objectives programs, incentive compensation, as well as IT and procurement functions. Prior to joining Idorsia, Bill spent 11 years leading Lupin Pharma’s US finance operations in Baltimore, MD, as VP-Finance, where he oversaw the development of the finance and IT infrastructure from the ground up. Before Lupin, Bill spent 11 years with K-V Pharmaceutical in St. Louis, MO, where he rose to VP-Business Planning and led the business planning and analysis function covering branded, generic and specialty raw material divisions, with overall responsibility for budgeting and forecasting, M&A valuations, strategic planning and corporate objectives programs. Bill also spent 7 years building and leading the corporate accounting team for Schein Pharmaceuticals in Florham Park, NJ.
Education: Bill earned both his MBA and BS in Accounting & Economics from Clarkson University.
Professional background: Fran Lillo was appointed Senior Director, Head of US Human Resources in May 2020. Prior to joining Idorsia, she was Human Resources Director at Janssen Research & Development LLC and supported the successful integration of Actelion's US Clinical Development organization following Janssen's acquisition of Actelion in June 2017. From 2005 - 2017, Fran helped drive the growth of Actelion's US Clinical Development organization through consistent focus on corporate core values and mission. Fran started her HR career in the consumer products sector at Hunt Corporation in Philadelphia, where, over a 16 year tenure, she was responsible for talent acquisition, benefits and compensation, and employee development and engagement.
Education: Fran holds a B.A. degree in Journalism from The Pennsylvania State University.
Professional background: Michael brings 22 years of marketing, sales and leadership experience spanning the pharmaceutical, device and diagnostic industries. He has worked across primary care, specialty and rare therapeutic areas. He joins us from Takeda Pharmaceuticals where he held the position of VP, US Hematology Franchise Lead and was responsible for a broad portfolio of rare disease products. Before his work at Shire and Takeda Michael was at Janssen Pharmaceuticals/J&J where he led the US Marketing efforts for Xarelto. Prior to that he was with Tethys Bioscience where he held the positions of Senior Marketing Director and Vice President of Sales and Operations. Previously he held US and global marketing positions at Merck, Schering- Plough and Millennium Pharmaceuticals.
Education: Michael holds a M.S. Ed. in Exercise Science and Wellness from Old Dominion University and B.S. in Sports Medicine from Marietta College.
Professional background: Eric is an attorney and compliance professional with more than twenty-five years of experience in the life sciences industry. Before joining Idorsia, he held the position of Vice President and Chief Compliance Officer for Jazz Pharmaceuticals in Philadelphia, Pennsylvania. Prior to that, he held the roles of Executive Vice President, General Counsel as well as Chief Compliance Officer for Incyte Corporation, a global biopharmaceutical company focused in Oncology, located in Wilmington, Delaware. Before joining Incyte, Eric served in senior management roles for EMD Serono, Solstice Neurosciences and Cephalon. He began his career in the pharmaceutical industry at SmithKline Beecham, now GlaxoSmithKline.
Education: Eric received his BA, Magna cum Laude, in Chemistry from Franklin and Marshall College, an MBA in Healthcare Administration from Temple University and his JD, cum Laude, from the University of Pennsylvania Law School.
Professional background: Paul brings 20 years of experience providing counsel in the pharmaceutical industry, at the Food and Drug Administration (FDA) and in private practice. He most recently served as Vice President, Legal, at Amarin Pharmaceuticals. He has led the legal and compliance functions as General Counsel at Braeburn Pharmaceuticals, and General Counsel and Chief Compliance Officer at Egalet Pharmaceuticals. Prior to that, he held various legal roles of increasing responsibility, including Assistant General Counsel, at GlaxoSmithKline. Paul also practiced FDA regulatory law at Reed Smith, and has served as Regulatory Counsel at the Center for Drug Evaluation and Research at FDA.
Education: Paul has a Juris Doctor from Temple University School of Law, a Master of Public Health from George Washington University, and a Bachelor of Arts from the College of William and Mary.
Professional background: Brian has 20 years of experience in the pharmaceutical industry with expertise in regulatory affairs for innovative investigational and branded pharmaceuticals across multiple therapeutic areas, including neurology, psychiatry, cardiovascular, and orphan diseases. He began his career at Wyeth Pharmaceuticals as a research scientist and transitioned into the regulatory affairs function. He subsequently held regulatory affairs roles of increasing responsibility at Shire Pharmaceuticals and Actelion Pharmaceuticals, including responsibility for several flagship products and oversite of investigational and new drug applications. When Actelion Pharmaceuticals was acquired by Janssen in 2017, Brian was appointed Vice President, Head of US Regulatory Affairs, leading all US regulatory activities for Idorsia, the newly formed company post-acquisition.
Education: Brian received his B.A. in Chemistry from Swarthmore College, M.A. in Neurosciences from Washington University in St. Louis, and an M.S. in Regulatory Affairs and Quality Assurance from Temple University.
Professional background: Joanna has three decades of broad commercial experience in the pharmaceutical industry working across multiple disease state categories while demonstrating her ability to build and lead teams and deliver results. Since September 2020, she has served as the Vice President and Head of US Sales at Idorsia. Prior to joining Idorsia, Joanna was the Franchise Head of the Rare Disease US Business Unit at Takeda Pharmaceutical Company, the organization’s largest product and revenue portfolio, where she navigated frequent internal transformation and intense external competition. Before Takada, Joanna spent 18 years at Johnson & Johnson, in a variety of functions and roles including: specialty and institutional sales, sales management (National Sales Director), sales training, and consumer and HCP marketing. Joanna is passionate about creating and leading high performing teams and fostering career development.
Education: Joanna received her B.A. from the University of Delaware.
Professional background: Chris has more than 20 years of experience in marketing and communications, 15 of which have been in the healthcare/pharmaceutical industry. Prior to his current role at Idorsia, Chris spent three years at Pfizer where he headed global communications for the Inflammation and Immunology division. Before this, Chris held leadership communications and marketing roles within several different therapeutic categories at Novo Nordisk, Bristol Myers Squibb and Endo Pharmaceuticals. Chris started his career in the industry with Johnson & Johnson. While Chris has deep experience in all communications disciplines, his focus has been on the commercial/product side, including product and indication launches, issues management and proactive and reactive media relations.
Education: Chris holds a B.S. from Millersville University.
Professional background: Dr. Ahuja is a cardiologist who has over two decades of experience as biopharmaceutical executive with a unique combination of business and scientific expertise. His leadership roles in Medical Affairs include serving as the Global Head of Medical Affairs for Allergan and Head of Medical Affairs for Hospira, launching multiple biologic compounds in distinct markets across the globe. He has also worked in Vice President roles at GlaxoSmithKline, Pfizer and Takeda Pharmaceuticals. Prior to that, he progressed through US and Global roles in Marketing, Strategy, Commercial Operations, and Business Development with Novartis and Tepha, Inc. earlier in his business career, while also working as an attending physician at Boston Children’s Hospital, Harvard Medical School.
Education: Dr. Ahuja earned a B.S. degree from Duke University, an M.D. degree from Washington University School of Medicine, and an M.B.A. from Harvard Business School.